title: [The several problems and cautions in treatment of Helicobacter pylori infection].
abstract: Helicobacter pylori (H. pylori) infection is the main cause of most gastroduodenal diseases; this discovery has been a major breakthrough in gastroenterology, hematology, dermatology and pediatrics. Triple therapy, including two antibiotics, amoxicillin and clarithromycin, and a proton pump inhibitor given for a week has been recommended as the treatment of choice in guideline for diagnosis and treatment of H. pylori infection in Japanese Journal of Helicobacter Research. However, this treatment may fail for several reasons including bacterial resistance. Our aim to review the problems and cautions in diagnosis and treatment of H. pylori infection.
authors.affiliation: Division of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Fukuda
authors.forename: Takashi
authors.initials: T
authors.lastname: Sakagami
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005744:Gastric Acid / Q000378:metabolism; D017408:Guidelines as Topic; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D054328:Proton Pump Inhibitors; D055502:Secondary Prevention; D013274:Stomach Neoplasms / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D000658:Amoxicillin; D017291:Clarithromycin